Venatorx Pharmaceuticals to Present in vitro and in vivo data for cefepime/VNRX-5133 at ECCMID 2018 Pipeline Corner Presentation, Mini Oral Sessions and Paper Poster Session to take place April 22-23 Malvern, PA, April 12, 2018 – Venatorx Pharmaceuticals announced that fourteen poster presentations, including four oral sessions, will feature its lead clinical antibacterial candidate, cefepime/VNRX-5133,...
Category: News
VenatoRx Pharmaceuticals to Present <em>in vitro</em> and <em>in vivo</em> data for cefepime/VNRX-5133 at ECCMID 2018
VenatoRx Pharmaceuticals to Present in vitro and in vivo data for cefepime/VNRX-5133 at ECCMID 2018 Pipeline Corner Presentation, Mini Oral Sessions and Paper Poster Session to take place April 22-23 Malvern, PA, April 12, 2018 – VenatoRx Pharmaceuticals announced that fourteen poster presentations, including four oral sessions, will feature its lead clinical antibacterial candidate, cefepime/VNRX-5133,...
VenatoRx Pharmaceuticals to Present its Lead Clinical Antibacterial Candidate, VNRX-5133, at the American Chemical Society National Meeting
VenatoRx Pharmaceuticals to Present its Lead Clinical Antibacterial Candidate, VNRX-5133, at the American Chemical Society National Meeting President and CEO, Christopher J. Burns, Ph.D., will present at the First-Time Disclosure of Clinical Candidates Oral Symposium on March 21, 2018 at 3:15pm CT Malvern, PA, March 19, 2018 – VenatoRx Pharmaceuticals announced that its President and...
Venatorx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens
Venatorx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens Malvern, PA, January 4, 2018 — Venatorx Pharmaceuticals, a private company dedicated to the discovery and development of novel therapies for highly drug resistant bacterial infections, announced that...
VenatoRx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens
VenatoRx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens Malvern, PA, January 4, 2018 — VenatoRx Pharmaceuticals, a private company dedicated to the discovery and development of novel therapies for highly drug resistant bacterial infections, announced that...
VenatoRx Pharmaceuticals Receives FDA’s QIDP and Fast Track Designations for Development of Its Lead Antibiotic Program
VenatoRx Pharmaceuticals Receives FDA’s QIDP and Fast Track Designations for Development of Its Lead Antibiotic Program Malvern, PA, January 3, 2018 — VenatoRx Pharmaceuticals, a private clinical-stage pharmaceutical company, announced today that the FDA has granted the company’s lead antibiotic program, VNRX-5133, an injectable broad-spectrum beta-lactamase inhibitor combined with a marketed beta-lactam antibiotic, both the...
Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris
Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris READ FULL TEXT
Fungal Cytological Profiling of Candida albicans Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A
Fungal Cytological Profiling of Candida albicans Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A READ FULL TEXT
Venatorx Pharmaceuticals Receives $9.4 Million From CARB-X To Develop A New Class Of Antibiotic To Combat Multi-drug Resistant Bacteria
Venatorx Pharmaceuticals Receives $9.4 Million From CARB-X To Develop A New Class Of Antibiotic To Combat Multi-drug Resistant Bacteria Malvern, PA, July 27, 2017 — Venatorx Pharmaceuticals, a private company dedicated to the discovery and development of novel therapies for highly drug resistant bacterial infections, announced that it has been awarded up to $9.4 million from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator)....
VenatoRx Receives $9.4 Million From CARB-X To Develop A New Class Of Antibiotic To Combat Multi-drug Resistant Bacteria
VenatoRx Receives $9.4 Million From CARB-X To Develop A New Class Of Antibiotic To Combat Multi-drug Resistant Bacteria Malvern, PA, July 27, 2017 — VenatoRx Pharmaceuticals, a private company dedicated to the discovery and development of novel therapies for highly drug resistant bacterial infections, announced that it has been awarded up to $9.4 million from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator). The...